Mark Dybul R.'s Insider Trades & SAST Disclosures
Mark Dybul R.'s most recent trade in Renovaro Biosciences Inc was a trade of 2,000,000 Option to Purchase Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Dybul R..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Renovaro Biosciences Inc | Dybul R. Mark | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 2,000,000 | 2,000,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark Dybul R. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 2,000,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 450,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 450,000 | 450,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Dybul R. Mark | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 350,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark Dybul R. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 350,000 | 350,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark Dybul R. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 300,000 | 300,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | R. Mark Dybul | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 300,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark Dybul R. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 7,563 | 7,563 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 7,563 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark Dybul R. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 5,226 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Dybul Mark R. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 5,226 | 5,226 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2022 | 350,000 | 350,000 | - | - | Option to purchase shares of common stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 2,000,000 | 2,000,000 | - | - | Option to purchase shares of common stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Executive Vice Chair | Other type of transaction at price $ 0.00 per share. | 14 Dec 2020 | 180 | 66,196 (0%) | 0% | 0 | Common Stock | |
| Renovaro Biosciences Inc | Mark R. Dybul | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 450,000 | 450,000 | - | - | Option to Purchase Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges